FLT3 and acute myeloid leukemia: ~35% of AML patients carry oncogenic mutations of FMS-like receptor tyrosine kinase 3 (FLT3) through either an internal tandem duplication (ITD) or a point mutation in the TK domain (TKD) of FLT3 (3).